Illness Perceptions and Response to Treatment with Romiplostim in Iraqi Patients with Refractory Immune Thrombocytopenia Purpura: A Cross-Sectional Study
Cross-sectional study assesses treatment response and illness perceptions in patients with immune thrombocytopenia, indicating a need for better education.
Key Points
Romiplostim demonstrated a 25% response rate in Iraqi patients with refractory immune thrombocytopenia, highlighting its effectiveness.
The study observed that 54.8% of patients reported bleeding complaints, affecting treatment perceptions significantly.
A cross-sectional study conducted with 84 ITP patients utilized Brief Illness Perception Questionnaires to measure perceptions related to treatment response.
Findings indicate that a low level of patient understanding exists, emphasizing the need for enhanced educational programs and counseling.